Boston Scientific stock slides after cyberattack threatens 2026 guidance

Boston Scientific's shares fell 2.3% in pre-market trading after the company delivered a formal warning that the cyberattack first identified on August 25 is now expected to have a material impact on its third-quarter and full-year 2026 results. According to the company, achieving the net sales growth and adjusted EPS guidance it had previously issued to investors now appears unlikely.

The disclosure, reported by Bloomberg, marks a significant escalation from the company's earlier stance, when it had said that the financial consequences of the breach were not yet determined.

The guidance retraction adds fresh pressure to a stock already contending with multiple headwinds this year.

Argus Research had previously downgraded the shares to Hold from Buy, citing growth concerns surrounding the Watchman device and the U.S. electrophysiology franchise. In parallel, Baird, JPMorgan, and Bank of America each cut their price targets following the second-quarter earnings report and the initial cyberattack disclosure.

TD Cowen provided a measure of support by reiterating its Buy rating and $56 price target, noting that the company's distribution network had been substantially restored as of its September 5 update, with major distribution centers processing and shipping products at or above normal levels. However, that constructive signal has been eclipsed by the formal financial warning.

The broader market is offering little buffer. The S&P 500 is modestly lower, the Dow Jones is down more meaningfully, and the NASDAQ is barely in positive territory, reflecting a cautious tone across U.S. equities. Medtech competitors Abbott and Medtronic have also navigated their own cybersecurity incidents in 2026, keeping sector sentiment subdued.

Taken together, the combination of a formal guidance-miss warning tied to the cyberattack, an earlier analyst downgrade, and a soft broader market environment has generated a convergence of selling pressure that is pushing Boston Scientific shares lower in pre-market trading. The stock now sits well below its 52-week high of $109.50 and closer to its 52-week low of $42.20.

This article was produced with the support of AI and reviewed by an editor. For more information, see our Terms and Conditions.